title: Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Padfield
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Leenah
authors.initials: L
authors.lastname: AlAhmari
authors.affiliation: The Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: Krystien V V
authors.initials: KV
authors.lastname: Lieve
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Tasneem
authors.initials: T
authors.lastname: AlAhmari
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Roston
authors.affiliation: The Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands; The Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, King Saud University, Jeddah, Kingdom of Saudi Arabia.
authors.forename: Arthur A
authors.initials: AA
authors.lastname: Wilde
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Krahn
authors.affiliation: Heart Rhythm Services, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: ssanatani@cw.bc.ca.
authors.forename: Shubhayan
authors.initials: S
authors.lastname: Sanatani
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D057915:Drug Substitution / Q000379:methods; D004361:Drug Tolerance; D004562:Electrocardiography / Q000379:methods; D005424:Flecainide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D054539:Medication Therapy Management; D018579:Patient Selection; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D061567:Voltage-Gated Sodium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects; D000098850:Polymorphic Catecholaminergic Ventricular Tachycardia
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D061567:Voltage-Gated Sodium Channel Blockers; D005424:Flecainide
keywords: Arrhythmia; Catecholaminergic polymorphic ventricular tachycardia; Flecainide; Side effects; Treatment; β-blockers